Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8361-8370 Newer>

Pharmaceutical Executive July 1, 2012 Ben Comer	John Lechleiter on PhRMA and Innovation Eli Lilly CEO John Lechleiter on his agenda as incoming chairman of PhRMA, US healthcare reform, the euro crisis, and the small problem, of innovation.
Pharmaceutical Executive July 1, 2012 Jill Wechsler	Who Will Pay for New Drugs? Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies.
Pharmaceutical Executive July 1, 2012 Al Topin	Marketing: Why the Conversation Has Changed -- Forever At its core, pharma marketing is about conversations. Dynamic, persuasive conversations between companies and healthcare stakeholders. But one time it was simple; now it's not.
Pharmaceutical Executive July 1, 2012 William Looney	Less, But Better Pharm Exec's 2012 roster of Emerging Leaders is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace.
Chemistry World July 5, 2012	Bayer buys crop protection firm for $425m German chemical and healthcare giant Bayer has struck a deal to buy US firm AgraQuest, which makes pest control products based on 'natural' or specially bred microorganisms.
Chemistry World July 3, 2012 Andrew Turley	BMS and AstraZeneca buy Amylin for $7bn Pharma giants Bristol-Myers Squibb and AstraZeneca have teamed up to buy US biotech Amylin for $7 billion, further strengthening their position in the burgeoning market for diabetes drugs.
Chemistry World July 3, 2012 Andrew Turley	US approves HIV home test kit The 'OraQuick' kit from US diagnostics firm OraSure, is already in use by clinics, but until now the company has not been allowed to market it for home use.
Chemistry World July 2, 2012 Andrew Turley	$3bn GSK fine sets new industry record The GlaxoSmithKline fine, which relates to antidepressant brands Paxil (paroxetine) and Wellbutrin (bupropion) and diabetes brand Avandia (rosiglitazone), is the largest payment ever made by a drug company.
Chemistry World July 2, 2012 Elinor Hughes	Why some metal hip replacements fail An investigation into why metal-on-metal hip joints fail long before other types of joints, such as metal-on-polyethylene and ceramic-on-ceramic, has revealed how the metal particles shed by the joints grinding against each other damage surrounding cells.
Chemistry World July 2, 2012 Michael Stow	Protecting the spirit of competition With the London 2012 Olympics now upon us, the issue of doping in sport is once more in the media spotlight. As new therapies emerge from the pharmaceutical industry, we must be vigilant for new doping threats and new and improved detection methods are continually investigated and developed.
<Older 8361-8370 Newer> Return to current articles.